Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Chemoprevention and Biological Therapies

Abstract B49: Use of MMTV-Neu/P53 KO transgenic mice to screen for potential chemopreventive agents

Ronald A. Lubet, Clinton J. Grubbs, Margaret Juliana, Ann Bode, Vernon E. Steele and Kenneth Iwata
Ronald A. Lubet
1National Cancer Institute, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clinton J. Grubbs
2University of Alabama, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret Juliana
2University of Alabama, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann Bode
3University of Minnesota, Austin, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vernon E. Steele
1National Cancer Institute, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Iwata
4OSI Pharmaceuticals, Long Island, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.PREV-10-B49 Published December 2010
  • Article
  • Info & Metrics
Loading
Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Nov 7-10, 2010; Philadelphia, PA

Abstract

The MMTV-Neu transgenic model of mammary cancer was developed almost 20 years ago in which mice develop Neu over-expressing ER- mammary cancers. Since human ER- Neu over-expressing mammary cancers often also have mutations in P53, a heterozygous KO of P53 was incorporated into the model. We used this model to examine a wide variety of potential chemopreventive agents. The agents were routinely administered to virgin female MMTV-Neu/P53 KO mice beginning when they were 60 days of age. Initiation at this time is somewhat later than is often employed in other laboratories (i.e., agents are typically started when mice are roughly 5-6 weeks of age). Mice were routinely monitored until 360 days of age. In agreement with Brown and colleagues (e.g., Cancer Res. 62: 6376-6380, 2002), it was found both RXR agonists (Targretin, UAB-30) and EGFR 1 and/or 2 inhibitors (Tarceva, Lapatinib) were highly effective in preventing the development of these cancers. More surprisingly, tamoxifen which is ineffective as a therapeutic agent against ER- breast cancer in women was effective in this model. It was also observed that a wide variety of agents were ineffective; including Atorvastatin, rosiglitazone (a PPAR gamma agonist), SAHA (an HDAC inhibitor), metformin, and a soy isoflavones mixture. In separate studies, mice bearing small palpable mammary tumors were treated for five days with these various agents, and examined for alterations in potential biomarkers; including proliferation. Effective agents (e.g., Iressa, Tarceva, and Targretin) strongly inhibited cancer cell proliferation, whereas ineffective agents failed to significantly inhibit proliferation. Thus, such a short-term assay might be employed to determine potential chemopreventive compounds. Short-term treatment with the EGFR inhibitors also decreased levels of expression of phosphorylated EGFR and downstream proteins; e.g., AKT/ERK. Supported by NCI contract number HHSN26120043301C.

Citation Information: Cancer Prev Res 2010;3(12 Suppl):B49.

  • Copyright © 2010, American Association for Cancer Research
Back to top
Cancer Prevention Research: 3 (12 Supplement)
December 2010
Volume 3, Issue 12 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract B49: Use of MMTV-Neu/P53 KO transgenic mice to screen for potential chemopreventive agents
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
Citation Tools
Abstract B49: Use of MMTV-Neu/P53 KO transgenic mice to screen for potential chemopreventive agents
Ronald A. Lubet, Clinton J. Grubbs, Margaret Juliana, Ann Bode, Vernon E. Steele and Kenneth Iwata
Cancer Prev Res December 1 2010 (3) (12 Supplement) B49; DOI: 10.1158/1940-6207.PREV-10-B49

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract B49: Use of MMTV-Neu/P53 KO transgenic mice to screen for potential chemopreventive agents
Ronald A. Lubet, Clinton J. Grubbs, Margaret Juliana, Ann Bode, Vernon E. Steele and Kenneth Iwata
Cancer Prev Res December 1 2010 (3) (12 Supplement) B49; DOI: 10.1158/1940-6207.PREV-10-B49
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Chemoprevention and Biological Therapies

  • Abstract PR09: Intermittent dosing regimens maintain efficacy of several cancer preventing drugs
  • Abstract PR03: Targeting multiple cell cycle regulatory points for the prevention of triple-negative breast cancer
  • Abstract PR05: Low dose aspirin that reduces mortality from lung adenocarcinoma inhibits both platelet COX-1 and the biosynthesis of PGE2
Show more Chemoprevention and Biological Therapies

Poster Presentations - Proffered Abstracts

  • Abstract B91: Functional polymorphisms in endogenous antioxidant defense genes and oxidative stress levels in women: A genotype-phenotype study
  • Abstract B86: Changes in social inequalities in male smoking-attributable mortality in two European countries
  • Abstract B96: Stimulation of lung adenocarcinoma by social stress
Show more Poster Presentations - Proffered Abstracts

Poster Presentations - Biological Agents

  • Abstract B50: Antiproliferative activity of the polar extract of Justicia spicigera on LNCaP cells
  • Abstract B48: Lack of efficacy of the anti-diabetic drug metformin in the ER+ methylnitrosourea (MNU)-induced and the ER- MMTV-Neu/p53KO models of mammary cancer
Show more Poster Presentations - Biological Agents
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement